Keys And Regulators Of Nanoscale Theranostics
Amineh Ghaderi1,§, Eduardo Antunez de Mayolo2,§, Hirak Kumar Patra1,§, Mohsen Golabi1,§, Onur Parlak1,§, Rickard Gunnarsson3,§, Raul Campos4,§, Revuri Vishnu1,§, Sami Elhag5,§, Selvakumar Subramanain1,§, Wetra Yandi6,§, Yuan Liu4,§, Yugal Agrawal1,§ and Ashutosh Tiwari1,7,*
1Biosensors and Bioelectronics Centre, IFM, Linkoping University, Linkoping 583 81, Sweden
2Institute of Experimental Physics, Otto-von-Güericke University Magdeburg, Germany
3Plasma & Coatings Physics Division, IFM-Materials, Physics, Linköping University, SE-581 83 Linköping, Sweden
4Department of Chemistry, IFM, Linkoping University, Linkoping 583 81, Sweden
5Department of Science and Technology, Campus Norrköping, Linköping University, Norrköping 60174, Sweden
6Molecular Physics, IFM, Linköping University, Linköping 583 81, Sweden
7Tekidag AB, Linkoping 58431, Sweden
§Authors contributed equally.
Adv. Mater. Lett., 2015, 6 (2), pp 87-98
Publication Date (Web): Feb 08, 2015
Copyright © 2019 VBRI Press
Nanoscale theragnosis is the biomedical aspect of nanomaterials for simultaneous diagnosis and therapy. The last decade was completely devoted by the scientist to combine the advancement in nanotechnology molecular biotechnology for the development of future nanomedicine. The approach started with the development of target-specific delivery of the cargo imaging molecule or drugs for biomedical applications. The cutting edge advantages of the nanoscale materials (e.g., large surface to volume ratio, size-shape dependent physicochemical properties and multi-functionality etc.) proved themselves as the most potential preferences to design optimal therapy for the personalized medicine. The present tutorial review will highlight the recent advances in the development on the regulation of such theragnosis system and their biomedical perspectives to act as a future nanomedicine.
Nanomedicine, theranostics, therapy, personalized medicine.